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Abstract
Mucopolysaccharidosis type II (Hunter syndrome; OMIM 309900) is a rare X-linked recessive lysosomal storage disorder
caused by the deficiency of the enzyme iduronate-2-sulfatase (IDS; EC 3.1.6.13). Different alterations at the IDS locus,
mostly missense mutations, have been demonstrated, by expression study, as deleterious, causing significant consequences on
the enzyme function or stability. In the present study we report on the results of the transient expression of the novel K347T,
533delTT, N265I and the already described 473delTCC (previously named vS117) mutations in the COS 7 cells proving their
functional consequence on IDS activity. This type of information is potentially useful for genotype^phenotype correlation,
prognosis and possible therapeutic intervention. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Mucopolysaccharidosis type II (Hunter syndrome;
OMIM 309900) is a rare X-linked recessive lysosom-
al storage disorder caused by the de¢ciency of the
enzyme iduronate-2-sulfatase (IDS; EC 3.1.6.13), re-
sponsible for heparan sulfate and dermatan sulfate
degradation. A broad spectrum of clinical pheno-
types has been observed ranging from the mild
form with late onset and absent or moderate mental
retardation to the severe neuronopathic form with
early death [1]. The IDS gene spans approx. 24 kb,
contains nine exons and is located on the Xq27/28
boundary of the long arm of the X-chromosome
(GenBank accession No. U66082) [2,3]. The IDS
full-length cDNA encodes a polypeptide of 550 ami-
no acids [4]. The biosynthesis and processing of the
IDS protein have been studied in overexpressing
transfected ¢broblasts; the enzyme is synthesized as
two precursor forms of 76 and 90 kDa that are con-
verted, through a 62 kDa intermediate, into 55 and
45 kDa mature polypeptides [5,6]. To date, more
than 200 di¡erent mutations have been identi¢ed at
the IDS locus; among these, some mutations, mostly
missense, have been demonstrated, by expression
study, as deleterious, causing signi¢cant consequen-
ces on the enzyme function or stability [7^10]. Three
novel mutations (K347T, 533delTT, N265I), as well
as the previously described 473delTCC (namely
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vS117) [7], identi¢ed in four out of 28 Italian pa-
tients were chosen to investigate in vitro their e¡ect
on enzyme expression. In the present study we report
these results and discuss the functional consequence
of the considered mutations on IDS activity and
maturation.
2. Materials and methods
2.1. Patients
The K347T, 533delTT, N265I, 473delTCC muta-
tions were identi¢ed during the mutational analysis
of a panel of Italian patients [11]. The MPS II diag-
nosis was based on the high excretion of heparan and
dermatan sulfate in urine and the IDS de¢ciency in
leukocytes and/or cell lines (¢broblasts or lympho-
blasts). Details about patients’ phenotypes and geno-
types are reported in Table 1.
2.2. Mutational analysis
Total RNA and DNA samples were extracted
from cultured ¢broblasts or lymphoblasts or periph-
eral lymphocytes using the standard protocols or
suitable kits (Qiagen).
Genomic DNA ampli¢cation was carried out by
sets of speci¢c primers £anking each exon. The
PCR ampli¢cation conditions were those reported
elsewhere [12]. Non-isotopic single strand conforma-
tion polymorphism (SSCP) was used for exon screen-
ing. The samples, selected on the basis of mobility
shift, were sequenced. To con¢rm the existence of the
mutations, restriction analysis was performed (Table
1). Reverse transcriptase-polymerase chain reaction
(RT-PCR) was performed using MLV reverse tran-
scriptase (BRL) and random hexanucleotide primers
(Promega) at 42‡C for 60 min followed by 5 min at
65‡C, in a total volume of 20 ml. The ¢rst strand
cDNA was PCR-ampli¢ed with the speci¢c primers
(exon 1F 5P-ATGCCGCCACCCGGACCGGCC
and exon 9R 5P-TCAAGGCATCAACAACTG-
GAAA). RT-PCR products were cloned in pCR2.1
(Invitrogen) and sequenced. Sequence analysis was
performed by an ABI 373A DNA automated se-
quencer with a dye terminator cycle sequencing kit
(Applied Biosystems).
2.3. Site directed mutagenesis
IDS expression plasmid pCAGGS-IDS [13] was
mutagenized using the commercially available Trans-
former II Kit (Clontech). Brie£y, the constructs were
generated using the pCAGGS vector containing the
normal IDS cDNA and two oligonucleotides: the
mutagenic primer, that contains the considered mu-
tation, and the selection primer (Sel-XhoI) that mu-
tates the unique SalI site in pCAGGS to a XhoI site,
according to the method described by Deng and
Nickolo¡ [14]. The mutant DNA strand was synthe-
sized and the parental DNA was linearized by diges-
tion with SalI for 2 h. By electroporation (one shot
at 2500 V, 25 mF, 200 W), the Escherichia coli mutS
cells were transformed using 2 Wg of the reaction
mixture; then, to increase the content of mutant
plasmids, the E. coli cells were grown in 5 ml LB
medium overnight in the presence of ampicillin.
Miniprep DNA, isolated by the Plasmid Mini Kit
(Qiagen), after a second round of digestion with
SalI, was electroporated into E. coli cells and grown
on plates overnight. The resulting colonies were
selected by restriction digestion analysis on the basis
of the absence of the SalI site and then sequenced to
verify the presence of the required mutations. The
sequences of the oligonucleotides used to introduce
the mutations into wild-type IDS cDNA and of the
selection primer are listed in Table 2.
Table 1
Patients’ data and details about the corresponding mutations
Phenotype Genotype Mutation description Exon Nucleotide change ERa site +/3 Protein alteration
Severe K347T missense VIII AAAsACA +MaeIII LyssThr
Intermediate N265I missense VI AACsATC +FokI Asns Ile
Severe 473delTCC in-frame deletion III TCCs9 +HphI Loss of a serine at codon 117
Severe 533delTT not in-frame deletion III TTTs ^T +Alw26I Chain termination
aER, enzyme restriction.
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2.4. COS cell transfection procedure
COS 7 cells were grown in Dulbecco’s modi¢ed
Eagle’s medium (DMEM), supplemented with 10%
FCS, 100 Wg/ml penicillin, 100 Wg/ml streptomy-
cin at 37‡C in a 5% CO2/air atmosphere. Ten
micrograms of wild-type and mutant cDNA ex-
pression vector constructs were introduced into
COS 7 cells by electroporation. The experimental
conditions were: 4^5U106 cells in a ¢nal volume of
800 Wl PBS without Ca2/Mg2, 10 Wg of plasmid
DNA, one shot at 1200 V, 25 WF, in a Bio-Rad
Gene Pulser apparatus. The cells, cultured in
100 mm2 petri dishes were harvested 48 h after
transfection, washed twice with 150 mM NaCl,
resuspended in the same bu¡er and sonicated. All
transfections were performed in triplicate. Each
triplicate underwent the Lowry assay [15] and the
IDS activity test, according to the method described
as follows.
2.5. Enzyme analysis
The tritiated disaccharide substrate, O-(a-L-idopy-
ranosyluronic acid 2-sulfate)-(1C4)-2,5-anhydro-D-
3H-mannitol-6-sulfate, is hydrolyzed by iduronate
sulfates to inorganic sulfate and the monosulfated
disaccharide product, O-(a-L-idopyranosyluronic
acid)-(1C4)-2,5-anhydro-D-3H-mannitol-6-sulfate.
To test for IDS activity, the cellular extracts were
dialyzed overnight against 4 l of distilled water.
IDS assay was performed by incubating 30 Wg of
proteins for 2 h with the radiolabeled disaccharide
substrate. To measure the activity of the enzyme in
the samples, the radioactive products were separated
from the substrate on an anion-exchange resin col-
umn [1].
2.6. Immunoblot analysis
Twenty micrograms of the total soluble cellular
extract were boiled 5 min in Laemmli bu¡er, electro-
phoresed through 10% SDS^PAGE and electroblot-
ted onto nitrocellulose membranes (Gelman Scien-
ces). The membranes were treated with 5% dry
milk in TTBS (20 mM Tris^HCl pH 7, 50 mM
NaCl, 0,1% Tween 20) to inhibit non-speci¢c bind-
ing. Anti-IDS polyclonal antiserum was used at a
1/1000 dilution in TTBS [10]. Visualization of antibody
binding was carried out with ECL (Amersham), ac-
cording to the manufacturer’s instructions.
3. Results
3.1. Mutational analysis
Three novel mutations (K347T, 533delTT and
N265I) and a previously described mutation
(473delTCC) [7] were identi¢ed during the mutation-
al analysis of a panel of Italian MPS II patients with
phenotypes ranging from the mild to the severe form
[11]. The A to C transversion was found in a patient
with the severe form of the disease, at cDNA posi-
tion 1164 (exon VIII) resulting in the replacement of
lysine for threonine at codon 347 (K347T). Another
transversion (A to T), detected in a patient a¡ected
by the intermediate clinical form, occurred at cDNA
position 918 (exon VI) causing the consequent re-
placement of asparagine for isoleucine at codon 265
(N265I). The 533delTT was a microdeletion of two
nucleotides at codon 137 causing a frameshift and
premature termination of translation at codon 143.
The lesion was detected in IDS exon III of a severely
a¡ected patient. The in-frame deletion of three nu-
cleotides at cDNA position 473 caused the loss of the
serine amino acid at codon 117 in a patient with
severe clinical manifestation of the disease. Patients’
genotypes and phenotypes are summarized in Table
1. All mutations, identi¢ed both by sequencing of the
cDNA and the genomic DNA, were also con¢rmed
by restriction endonuclease analysis.
3.2. Expression study
The functional consequence of the K347T,
Table 2
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533delTT, N265I and 473delTCC mutations on IDS
enzyme were evaluated by in vitro expression of the
related mutant proteins and studied through activity
measurements and Western blot analysis. After
transfection of COS 7 with the wild-type and mutant
plasmids, cells transfected with wild-type IDS cDNA
had an activity of 394.8 U/mg protein, resulting in a
32-fold increase in comparison with untransfected
cells that showed an IDS activity of 12.3 U/mg pro-
tein. No signi¢cant IDS activity was found in cells
expressing K347T, 533delTT and 473delTCC muta-
tions (Table 3).
In the cells expressing the normal IDS cDNA the
immunoblot analysis showed the 55 kDa band cor-
responding to the mature form of the enzyme, where-
as neither the 90 kDa precursor nor the 62 kDa
intermediate forms were detectable [5,10]. The most
likely explanation is that a batch of antibody di¡er-
ent from that used previously [10] could be respon-
sible for the misdetection of the 90 kDa and 62 kDa
forms. Indeed, pulse-chase experiments of COS cells
expressing normal cDNA con¢rmed that this new
batch of antibody was not able to recognize the pre-
cursor form (data not shown). The cells transfected
with the K347T, 473delTCC and N265I mutations
presented similar results, even though the band of
55 kDa was less intense with respect to the wild-
type enzyme. In contrast, no protein form was re-
vealed in cells transfected with the cDNA containing
the 533delTT mutation (Fig. 1).
4. Discussion
An important question arises as to whether or not
a single base pair change is indeed the pathological
lesion causing disease. The major evidence of causal-
ity for novel mutations should involve in vitro ex-
pression of the mutant gene to verify the enzymatic
defect. To date, however, in vitro expression experi-
ments are rarely applied, probably because of tech-
nical di⁄culty. As reviewed recently [16], some ex-
pression studies utilized Western blot analysis
showing the presence of the precursor but not of
the mature IDS form; some other studies, based on
pulse-chase labeling experiments, resulted in the pres-
ence of a normal amount of precursor; ¢nally, only
subcellular fractionation studies demonstrated a gen-
eralized high proportion of IDS polypeptide content
in an early vacuolar compartment, although Western
blot and pulse-chase experiments resulted apparently
normal [10]. In this study, in order to evaluate the
functional consequence of the K347T, 533delTT,
N265I and 473delTCC mutations on IDS enzyme,
related mutant proteins were expressed in vitro and
studied through activity measurements and Western
blot analysis.
Our data proved the deleterious nature of the
K347T, N265I, 473delTTC and 533delTT mutations.
Both K347T and N265I are missense mutations oc-
curring in residues not evolutionary conserved [17].
Fig. 1. Immunoblot analysis of COS 7 cells transiently trans-
fected with mutants and wild-type (WT) constructs. After trans-
fection and cell lysis, an equal loading of protein (20 Wg) was
used for each sample. The last lane (COS) is referred to un-
transfected COS cells. Weights of the molecular mass markers
(in kDa) are shown on the left.
Table 3
IDS activity in COS 7 transfected with wild-type and mutant
cDNAs







aIDS activity values are the average of three di¡erent transfec-
tions.
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However, the K347T construct expressed an IDS ac-
tivity completely overlapping that of untransfected
COS cells, correlating with the severe clinical mani-
festations of the patient. On the other hand, the
N265I construct expressed a residual activity (7.5%
of the wild-type activity) probably related to the in-
termediate form of the disease. Both the 473delTCC
and 533delTT microdeletions, in-frame and not in-
frame, respectively, presented no signi¢cant IDS ac-
tivity. Intriguingly, when the mutant constructs
underwent Western blot analysis, the K347T,
473delTCC and N265I mutations yielded the 55
kDa mature form, as the wild-type construct, sug-
gesting that alterations in these positions do not in-
hibit formation of the mature 55 kDa polypeptide,
whereas no cross-reacting material was revealed in
case of the 533delTT mutation, suggesting that the
predicted premature stop codon could a¡ect protein
synthesis and/or stability. It should also be noted
that skipping of serine 117, although not altering
IDS maturation, results in an inactive enzyme, as
reported for a mutation at the contiguous amino
acid, T118I [10]. However, in this last case the in-
volved missense alteration was found in a mildly af-
fected patient, probably due to the marked amount
(78%) of IDS polypeptides achieving a normal lyso-
somal localization; therefore, it is possible that poly-
peptides lacking serine 117 are not able to reach
lysosomes in signi¢cant amounts, accounting for
the severe phenotype of the involved patient.
In conclusion, we have con¢rmed as deleterious
the K347T, N265I, 473delTCC and 533delTT muta-
tions in the IDS gene demonstrating that at least the
¢rst three molecular defects do not a¡ect IDS pro-
cessing but have possible e¡ects on enzyme confor-
mation and function. This type of information is
potentially useful for genotype^phenotype correla-
tion, prognosis and possible therapeutic intervention.
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